{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T09:56:31Z","timestamp":1783850191104,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA65493"],"award-info":[{"award-number":["P01 CA65493"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000885","name":"Children's Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["R6029-07"],"award-info":[{"award-number":["R6029-07"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.bbmt.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T00:34:41Z","timestamp":1470789281000},"page":"2025-2030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor\u2013Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation"],"prefix":"10.1016","volume":"22","author":[{"given":"Nelli","family":"Bejanyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rogosheske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"DeFor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Lazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shernan G.","family":"Holtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamala A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"MacMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Verneris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio G.","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.08.005_bib0010","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/j.1600-6143.2011.03558.x","article-title":"Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease","volume":"11","author":"Hippen","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0020","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/j.1600-6143.2012.04269.x","article-title":"Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients","volume":"12","author":"Akimova","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0025","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/leu.2014.180","article-title":"Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors","volume":"29","author":"Peccatori","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1749-6632.1993.tb35854.x","article-title":"Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administered during the graft-versus-host disease process","volume":"685","author":"Blazar","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0035","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.4049\/jimmunol.151.10.5726","article-title":"Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome","volume":"151","author":"Blazar","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0040","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13931","article-title":"The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0045","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbmt.2003.12.305","article-title":"Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation","volume":"10","author":"Cutler","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0050","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0055","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/CEOR.S51446","article-title":"Budget impact analysis of conversion from cyclosporine to sirolimus as immunosuppressive medication in renal transplantation therapy","volume":"5","author":"Foroutan","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10198-014-0579-3","article-title":"Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany","volume":"16","author":"Jurgensen","year":"2015","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0065","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1200\/JCO.2008.17.7279","article-title":"Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning","volume":"26","author":"Armand","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0070","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2010.192","article-title":"Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis","volume":"46","author":"Cutler","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0075","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.07657.x","article-title":"Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies","volume":"145","author":"Teachey","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0085","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1182\/blood-2003-02-0489","article-title":"Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation","volume":"102","author":"Antin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0090","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.bbmt.2008.05.024","article-title":"Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation","volume":"14","author":"Alyea","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0095","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.bbmt.2010.09.017","article-title":"Prophylaxis with sirolimus and tacrolimus +\/\u2212 antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation","volume":"17","author":"Rosenbeck","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0100","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.bbmt.2012.06.004","article-title":"Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation","volume":"18","author":"Al-Kadhimi","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0105","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2009-03-207563","article-title":"A phase II pilot study of tacrolimus\/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens","volume":"115","author":"Rodriguez","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0110","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.leukres.2012.04.022","article-title":"Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus\/sirolimus-based GVHD prophylaxis","volume":"36","author":"Nakamura","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0115","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","article-title":"A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0120","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3324\/haematol.2012.065599","article-title":"The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate","volume":"98","author":"Perez-Simon","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0125","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2007-04-067215","article-title":"Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease","volume":"110","author":"Brunstein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0130","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bbmt.2015.01.023","article-title":"Higher dose of mycophenolate mofetil reduces acute graft-versus-host disease in reduced-intensity conditioning double umbilical cord blood transplantation","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0135","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0140","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2008-07-163238","article-title":"Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors","volume":"113","author":"MacMillan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0145","series-title":"American Society for Blood and Marrow Transplantation RFI","author":"ASBMT","year":"2006"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0150","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0160","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M","article-title":"Non-parametric inference for cumulative incidence functions in competing risks studies","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0165","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0170","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/bmt.2011.104","article-title":"Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation","volume":"47","author":"Johnston","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0175","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0180","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/bmt.2012.175","article-title":"A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant","volume":"48","author":"Khaled","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0185","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1177\/1060028015593369","article-title":"Transplantation-associated thrombotic microangiopathy in patients treated with sirolimus and cyclosporine as salvage therapy for graft-versus-host disease","volume":"49","author":"Garcia-Martin","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0190","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.005_bib0195","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ctrv.2006.10.004","article-title":"Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma","volume":"33","author":"Costa","year":"2007","journal-title":"Cancer Treat Rev"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116302804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116302804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:57:06Z","timestamp":1761058626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116302804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1083879116302804"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.08.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor\u2013Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}